GlassScriptPhysician profile
Alisha Renteria
NPI 1063933422
$2,175.91
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $104 · 2022: $180 · 2023: $1,277 · 2024: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,892.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,891.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $170.19 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $165.72 | 2023-2024 | Jardiance, Mounjaro, Emgality |
| Amgen INC. | $138.50 | 2023-2024 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.34 | 2022-2024 | Jardiance |
| Pfizer INC. | $133.73 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $111.83 | 2023-2024 | Farxiga, Breztri, Airsupra |
| Medline Industries LP | $109.61 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $106.70 | 2023-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $90.10 | 2022-2024 | Spravato, Xarelto |
| Merck Sharp & Dohme LLC | $84.89 | 2023-2024 | Verquvo, Belsomra |
| Bayer Healthcare Pharmaceuticals INC. | $76.71 | 2023-2024 | |
| Abbvie INC. | $62.97 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.89 | 2023-2024 | Trintellix |
| Glaxosmithkline, LLC. | $62.39 | 2021-2024 | Trelegy Ellipta |
| Mayne Pharma Commercial LLC | $56.40 | 2023-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $54.07 | 2023 | Quviviq |
| Halozyme INC | $52.16 | 2023 | |
| Astellas Pharma US INC | $52.09 | 2023-2024 | Veozah |
| Medtronic, INC. | $50.19 | 2023 | Intellis Adaptivestim |
| Qiagen, LLC | $38.07 | 2023 | |
| Mylan Specialty L.P. | $37.07 | 2023-2024 | Yupelri |
| Cranial Technologies, INC | $33.09 | 2021-2023 | Doc Band |
| Stryker Corporation | $32.48 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $26.55 | 2023 | Inpefa |
| Corcept Therapeutics | $25.51 | 2023 | Korlym |
| Nestle Healthcare Nutrition INC. | $25.04 | 2023 | |
| Daiichi Sankyo INC. | $24.98 | 2024 | Injectafer |
| Roche Diagnostics Corporation | $22.66 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $22.34 | 2021 | |
| Lundbeck LLC | $21.86 | 2024 | Rexulti |
| Ironwood Pharmaceuticals, INC | $17.30 | 2024 | |
| Esperion Therapeutics, INC. | $16.44 | 2023 | Nexletol |
| Phathom Pharmaceuticals, INC. | $14.71 | 2024 | Voquezna |
| Organon LLC | $14.42 | 2023 | Nexplanon |
| Novartis Pharmaceuticals Corporation | $14.19 | 2024 | |
| Dexcom, INC. | $13.72 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alisha Renteria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.